194032-49-0

Basic information

• Product Name: RaceMic tert-butyl 3,6-diazabicyclo[3.2.1]octane-6-carboxylate
• Synonyms: RaceMic tert-butyl 3,6-diazabicyclo[3.2.1]octane-6-carboxylate;RaceMic tert-butyl 3,6-diazabicyclo[3.2.1]octane-6-carboxylate hydrochloride;(1S,5R)-TERT-BUTYL 3,6-DIAZABICYCLO[3.2.1]OCTANE-6-CARBOXYLATE
• CAS NO: 194032-49-0
• Molecular Formula: C₁₁H₂₀N₂O₂
• Molecular Weight: 212.2887
• Mol File: 194032-49-0.mol

Chemical Properties

• Boiling Point: 295.4±13.0 °C(Predicted)
• Appearance: /
• Density: 1.076±0.06 g/cm3(Predicted)
• PKA: 10.78±0.20(Predicted)
• CAS DataBase Reference: RaceMic tert-butyl 3,6-diazabicyclo[3.2.1]octane-6-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: RaceMic tert-butyl 3,6-diazabicyclo[3.2.1]octane-6-carboxylate(194032-49-0)
• EPA Substance Registry System: RaceMic tert-butyl 3,6-diazabicyclo[3.2.1]octane-6-carboxylate(194032-49-0)

Safety Data

• Hazardous Substances Data: 194032-49-0(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
RaceMic tert-butyl 3,6-diazabicyclo[3.2.1]octane-6-carboxylate is used as a reagent in chemical synthesis for its ability to facilitate various organic reactions, enhancing the efficiency and selectivity of the processes.
Used in Catalyst Applications:
As a catalyst, RaceMic tert-butyl 3,6-diazabicyclo[3.2.1]octane-6-carboxylate is employed to accelerate chemical reactions without being consumed in the process, making it a cost-effective and sustainable choice for industrial applications.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, RaceMic tert-butyl 3,6-diazabicyclo[3.2.1]octane-6-carboxylate is used as an intermediate in the synthesis of various drug molecules, contributing to the development of new medications and therapies.
Used in Research and Development:
RaceMic tert-butyl 3,6-diazabicyclo[3.2.1]octane-6-carboxylate is utilized in research and development settings to explore its potential applications and properties, further expanding its use in various chemical and scientific fields.

Upstream product

• 848591-67-3 tert-butyl 2,4-diformylpyrrolidine-1-carboxylate 
• 1058737-58-8 tert-butyl 2,4-bis(hydroxymethyl)pyrrolidine-1-carboxylate 
• 49805-30-3 2-azabicyclo[2.2.1.]hept-5-en-3-one 
• 1058737-59-9 tert-butyl 2,4-bis((methylsulfonyloxy)methyl)pyrrolidine-1-carboxylate 
• 188345-71-3 2-(tert-butoxycarbonyl)-2-azabicyclo[2.2.1]hept-5-ene 
• 24424-99-5 di-tert-butyl dicarbonate 
• 848591-68-4 tert-butyl 3-benzyl-3,6-diazabicyclo[3.2.1]octane-6-carboxylate 

Downstream Products

• 1001856-75-2 C₂₁H₂₇N₅O₃ 
• 848591-69-5 3-(6-Phenyl-pyridazin-3-yl)-3,6-diaza-bicyclo[3.2.1]octane-6-carboxylic Acid Tert-Butyl Ester 

Relevant articles and documents

BRIDGED DIAZEPANE OREXIN RECEPTOR ANTAGONISTS

The present invention is directed to bridged diazepane compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS

Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

AMIDES OF DIAZABICYCLOOCTANES AND USES THEREOF

The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (CNS).

Design and synthesis of conformationally constrained N,N-disubstituted 1,4-diazepanes as potent orexin receptor antagonists

Orexins are neuropeptides that regulate wakefulness and arousal. Small molecule antagonists of orexin receptors may provide a novel therapy for the treatment of insomnia and other sleep disorders. In this Letter we describe the design and synthesis of con

HETEROCYCLIC-CARBONYL-DIAZABICYCLOALKANES AS MODULATORS OF THE NEURONAL NICOTINIC ACETYLCHOLINE ALPHA 4 BETA 2, SUBTYPE RECEPTOR FOR THE TREATMENT OF CNS RELATED DISORDERS

A compound of Formula 1: A-C(O)-Cy, wherein A is a diazabicyclic core, containing 7, 8, or 9 ring atoms, and selected from the following: 2,6-diazabicyclo[3.2.0]heptane; 3,6-diazabicyclo[3.ZO]heptane; 2,7-diazabicyclo[4.2.0]octane; 3,7-diazabicyclo[4.2.0]octane; 3,8-diazabicyclo[4.2.0]octane; 2,7-diazabicyclo[3.3.0]octane; 2,7-diazbicyclo[4.3.0]nonane; 2,8-diazbicyclo[4.3.0]nonane; 3,7-diazabicyclo[4.3.0]nonane; 3,8-diazabicyclo[4.3.0]nonane; 3,9-diazabicyclo[4.3.0]nonane; 2,6-diazabicyclo[3.2.1 ]octane; 3,6-diazabicyclo[3.2.1]octane; wherein the diazabicycle is attached as a radical to the depicted carbonyl via either one of the two ring nitrogen atoms, such that the carbonyl forms an amide bond with the ring nitrogen; Cy is a heteroaryi group; The compounds exhibit selectivity for, and bind with high affinity to, neuronal nicotinic receptors of the α402 subtype in the central nervous system (CNS). The compounds and compositions can be used to treat and/or prevent a wide variety of conditions or disorders, particularly CNS disorders. The compounds are believed to: (i) alter the number of nicotinic cholinergic receptors of the brain of the patient, (ii) exhibit neuroprotective effects, and (iii) when employed in effective amounts, not result in appreciable adverse side effects, namely side effects such as significant Increases in blood pressure and heart rate, significant negative effects upon the gastrointestinal tract, and significant effects upon skeletal muscle.

Structure-activity studies and analgesic efficacy of N-(3-pyridinyl)- bridged bicyclic diamines, exceptionally potent agonists at nicotinic acetylcholine receptors

A series of exceptionally potent agonists at neuronal nicotinic acetylcholine receptors (nAChRs) has been investigated. Several N-(3-pyridinyl) derivatives of bridged bicyclic diamines exhibit double-digit-picomolar binding affinities for the α4β2 subtype, placing them with epibatidine among the most potent nAChR ligands described to date. Structure-activity studies have revealed that substitutions, particularly hydrophilic groups in the pyridine 5-position, differentially modulate the agonist activity at ganglionic vs central nAChR subtypes, so that improved subtype selectivity can be demonstrated in vitro. Analgesic efficacy has been achieved across a broad range of pain states, including rodent models of acute thermal nociception, persistent pain, and neuropathic allodynia. Unfortunately, the hydrophilic pyridine substituents that were shown to enhance agonist selectivity for central nAChRs in vitro tend to limit CNS penetration in vivo, so that analgesic efficacy with an improved therapeutic window was not realized with those compounds.

Substituted diazabicycloakane derivatives

Compounds of formula (I) Z-Ar1—Ar2??(I) wherein Z is a diazabicyclic amine, Ar1 is a 5- or 6-membered aromatic ring, and Ar2 is selected from an unsubstituted or substituted 5-membered heteroaryl ring; an unsubstituted or substituted 6-membered heteroaryl ring; 3,4-(methylenedioxy)phenyl; and phenyl substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.

Substituted diazabicycloalkane derivatives

Compounds of formula (I) [in-line-formulae]Z-Ar1—Ar2??(I) [/in-line-formulae] wherein Z is a diazabicyclic amine, Ar1 is a 5- or 6-membered aromatic ring, and Ar2 is selected from the group consisting of an unsubstituted or substituted 5- or 6-membered heteroaryl ring; unsubstituted or substituted bicyclic heteroaryl ring; 3,4-(methylenedioxy)phenyl; carbazolyl; tetrahydrocarbazolyl; naphthyl; and phenyl; wherein the phenyl is substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.